ReviewCancers2019
Perioperative Treatment in Resectable Gastric Cancer: Current Perspectives and Future Directions.
Review in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Association between neutrophil-lymphocyte ratio and lymph node metastasis in gastric cancer: A meta-analysis.Medicine · 2022Pooled it
- Pathologic Response and Outcomes After Neoadjuvant Chemotherapy in Gastric Cancer: A NCDB Analysis.Journal of surgical oncology · 2026Article
- Article
- Knowledge, attitudes, and practices toward nutritional management among patients with gastrointestinal cancer: A cross-sectional study.Asia-Pacific journal of oncology nursing · 2025Article
- CIAO1 as a crucial signature gene of cuproptosis in gastric cancer.Oncology letters · 2025Article
- Long-term outcome after perioperative chemotherapy and surgery for gastro-esophageal adenocarcinoma.ESMO gastrointestinal oncology · 2025Article
- Updated long-term survival outcomes for patients with locally advanced gastric cancer having pathological complete response after neoadjuvant therapy at China National Cancer Center, 2004-2023.Frontiers in oncology · 2025Article
- Current status of neoadjuvant immunotherapy for the treatment of gastric cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Review
- Current status and future trends of real-time imaging in gastric cancer surgery: A literature review.Heliyon · 2024Review
- Neoadjuvant Therapies for Patients with Locally Advanced Gastric Cancer: A Retrospective Cohort Study.The Eurasian journal of medicine · 2024Article
- Application of Survival Quilts for prognosis prediction of gastrectomy patients based on the Surveillance, Epidemiology, and End Results database and China National Cancer Center Gastric Cancer database.Journal of the National Cancer Center · 2024Article
- Role of the microbiome in the development and treatment of gastric cancer: an overview of the biological and clinical landscape.ESMO gastrointestinal oncology · 2024Review
- Circular RNA CDR1as Mediated by Human Antigen R (HuR) Promotes Gastric Cancer Growth via miR-299-3p/TGIF1 Axis.Cancers · 2023Article
- Perioperative Modified FLOT Versus EOX in Locally Advanced Resectable Gastric and Gastro-Oesophageal Junction Adenocarcinoma: Results of a Matched-Pair Analysis.Journal of gastrointestinal cancer · 2023Article
- Evaluation of Pathological Response Rate and Complications of FOLFOX versus FLOT Regimen in Perioperative Chemotherapy for Resectable Gastric Cancer: A Prospective Study.Asian Pacific journal of cancer prevention : APJCP · 2023Article
- Outcome evaluation of ECF, DCF, FOLFOX, and FLOT chemotherapy regimens as perioperative treatment in elderly patients with resectable gastric cancer; A retrospective comparative study.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2023Article
- Reconstruction of the gastric cancer microenvironment after neoadjuvant chemotherapy by longitudinal single-cell sequencing.Journal of translational medicine · 2022Article
- Efficacy and safety of FLOT regimenResearch in pharmaceutical sciences · 2022Article
- Prognostic factors of perioperative FLOT regimen in operable gastric and gastroesophageal junction tumors: real-life data (Turkish Oncology Group).Turkish journal of medical sciences · 2022Article
- Nutritional Status and Related Factors in Patients with Gastric Cancer after Gastrectomy: A Cross-Sectional Study.Nutrients · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric cancer (GC) is the fifth-most common cancer worldwide and an important cause of cancer-related-death. The growing knowledge of its molecular pathogenesis has shown that GC is not a single entity, but a constellation of different diseases, each with its own molecular and clinical characteristics. Currently, surgery represents the only curative approach for localized GC, but only 20% of patients (pts) showed resectable disease at diagnosis and, even in case of curative resection, the prognosis remains poor due to the high rate of disease relapse. In this context, multimodal perioperative approaches were developed in western and eastern countries in order to decrease relapse rates and improve survival. However, there is little consensus about the optimal treatment for non-metastatic GC. In this review, we summarize the current status and future developments of perioperative chemotherapy in resectable GC, attempting to find clear answers to the real problems in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.